Is there evidence that radiotherapy to less than all sites of oligometastatic prostate cancer is beneficial?

For example, for a biochemically recurrent patient now with 4 PSMA PET+ nodes, if one of those PSMA+ pelvic nodes is within the prior field and adjacent to previously irradiated bowel/bladder near normal tissue tolerance levels before, would there be any value in irradiating the 3 other oligometastatic nodes?

Answer from: Radiation Oncologist at Academic Institution

The ORIOLE trial referenced above helps to answer this question. Within the SBRT arm (n=36), patients received PSMA PET, however, the treating rad oncs were blinded to the result and patients were "consolidated" based on conventional imaging. Treatment plans were then reviewed and compared to PSMA, ...

Comments

Radiation Oncologist at The Oregon Clinic-Radiation Oncology West
A hypothesis from STAMPEDE is that the survival be...

Answer from: Radiation Oncologist at Community Practice

STAMPEDE (Parker et al., PMID 30355464; Ali et al., PMID 33599706) reported benefit of prostate-only radiotherapy for patients with low metastatic burden with the greatest benefit for M1a (non-regional nodes) or 3 or fewer bone metastases without visceral metastases. For patients with prior pro...

Please select the option that best describes you:

Is there evidence that radiotherapy to less than all sites of oligometastatic prostate cancer is beneficial?

Related Questions